← All trials
NCT02493985
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2015
- Primary completion
- Jul 31, 2015
- Completion date
- Jul 31, 2015
- First posted
- Jul 10, 2015
- Last posted
- Jan 13, 2016
- Enrollment
- 6
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Baylor UniversityLead sponsor
- Baylor UniversityReponsible party - principal investigator
- DLR German Aerospace CenterCollaborator
- Harvard UniversityCollaborator
- University of Texas at HoustonCollaborator
- University of CologneCollaborator
- University of PennsylvaniaCollaborator
- National Space Biomedical Research InstituteCollaborator
- Baylor UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.